Bradford Perez, MD

Cancer Focus:
Lung Cancer, Mesothelioma, Pancoast Tumor, Thymoma

Dr. Perez specializes as an oncologist who utilizes radiation therapy to treat patients with lung cancer and other thoracic malignancies including mesothelioma and thymoma. This radiation therapy includes the use of advanced techniques such as stereotactic body radiation therapy (SBRT), image-guided radiation therapy (IGRT), and intensity modulated radiation therapy (IMRT) to deliver treatment, as appropriate in both curative and palliative circumstances. Dr. Perez is interested in integration of radiation therapy with novel systemic agents including immunotherapeutics for the treatment of patients with lung cancers and mesothelioma. Additionally, he has a strong interest in combining each patient’s clinical situation with detailed information regarding the molecular makeup of their tumor to improve delivery of personalized radiation therapy for patients with thoracic malignancies. Dr. Perez earned his medical degree and completed his residency in Radiation Oncology at Duke University School of Medicine.

Education & Training

Residency:

• Duke University School of Medicine - Radiation Oncology

Medical School:

• Duke University School of Medicine - MD

Clinical Trial 21525
A Feasibility Study of Genomically Guided Radiation Dose Personalization in the Management of Locally Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Radiotherapy ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Sandoval ML, Sim AJ, Bryant JM, Bhandari M, Wuthrick EJ, Perez BA, Dilling TJ, Redler G, Andreozzi J, Nardella L, Feygelman V, Latifi K, Rosenberg SA. Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions. JTO Clin Res Rep. 2023 May.4(5):100488. Pubmedid: 37159821. Pmcid: PMC10163640.
• Martin AL, Powell C, Nagy MZ, Innamarato P, Powers J, Nichols D, Anadon CM, Chaurio RA, Kim S, Wang MH, Gong B, Wang X, Scheutz TJ, Antonia SJ, Conejo-Garcia JR, Perez BA. Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. Cancer Immunol Immun. 2023 Jun.72(6):1445-1460. Pubmedid: 36469096.
• Kozee M, Weygand J, Andreozzi JM, Hunt D, Perez BA, Graham JA, Redler G. Methodology for computed tomography characterization of commercially available 3D printing materials for use in radiology/radiation oncology. J Appl Clin Med Phys. 2023 Jun.24(6):e13999. Pubmedid: 37096305. Pmcid: PMC10243336.
• Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, Feldman J, Gomez DR, Hesketh PJ, Jabbour SK, Jeter M, Josipovic M, Lievens Y, McDonald F, Perez BA, Ricardi U, Ruffini E, De Ruysscher D, Saeed H, Schneider BJ, Senan S, Widder J, Guckenberger M. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023 Jun.13(5):393-412. Pubmedid: 37294262.
• Wong HCY, Chan AW, Johnstone P, Simone CB, Navarro-Domenech I, Hoskin P, Johnstone C, Recht A, Menten J, van der Linden YM, van der Velden JM, Nguyen QN, Lutz S, Andratschke N, Wilmann J, Kazmierska J, Spalek M, Lim F, Yu HM, Perez B, Marta GN, Vassiliou V, Lee SF, Bonomo P, Rembielak A, Chow E, Oldenburger E, Raman S. A critical appraisal of the four systematic reviews and meta- analysis on stereotactic body radiation therapy versus external beam radiotherapy for painful bone metastases and where we go from here. Ann Palliat Med. 2023 Jun. Pubmedid: 37303218.
• Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
• Oliver DE, Laborde JM, Singh DP, Milano MT, Videtic GM, Williams GR, Lariviere MJ, Chan JW, Peters GW, Decker RH, Samson P, Robinson CG, Breen WG, Owen D, Tian S, Higgins KA, Almeldin D, Jabbour SK, Wang F, Grass GD, Perez BA, Dilling TJ, Strosberg J, Rosenberg SA. Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):849-857. Pubmedid: 36708788.
• Zheng H, Yu X, Ibrahim ML, Foresman D, Xie M, Johnson JO, Boyle TA, Ruffell B, Perez BA, Antonia SJ, Ready N, Saltos AN, Cantwell MJ, Beg AA. Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunol Res. 2023 Apr.11(4):466-485. Pubmedid: 36757308. Pmcid: PMC10165690.
• Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
• Dohm AE, Tang JD, Mills MN, Liveringhouse CL, Sandoval ML, Perez BA, Robinson TJ, Creelan BC, Gray JE, Etame AB, Vogelbaum MA, Forsyth P, Yu HM, Oliver DE, Ahmed KA. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. J Neurosurg. 2022 Nov.1-8. Pubmedid: 36681988.
• Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494. Pmcid: PMC9096229.
• Martin AL, Anadon CM, Biswas S, Mine JA, Handley KF, Payne KK, Mandal G, Chaurio RA, Powers JJ, Sprenger KB, Rigolizzo KE, Innamarato P, Harro CM, Mehta S, Perez BA, Wenham RM, Conejo-Garcia JR. Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Mol Cancer Ther. 2022 Jul.21(7):1184-1194. Pubmedid: 35499393. Pmcid: PMC9256805.
• Robinson LA, Fontaine J, El-Haddad G, Bryant S, Perez B, Toloza E, Kis B. Novel Subdiaphragmatic Ligation of Left Thoracic Duct for Refractory Postoperative Left Chylothorax. Ann Thorac Surg. 2022 Jan.113(1):e29-e31. Pubmedid: 33794166.
• Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022 Jan.55(1):115-128.e9. Pubmedid: 35021053. Pmcid: PMC8852221.
• Turner K, Brownstein NC, Thompson Z, El Naqa I, Luo Y, Jim HSL, Rollison DE, Howard R, Zeng D, Rosenberg SA, Perez B, Saltos A, Oswald LB, Gonzalez BD, Islam JY, Alishahi Tabriz A, Zhang W, Dilling TJ. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy. Radiother Oncol. 2022 Feb.167:116-121. Pubmedid: 34953934. Pmcid: PMC8934278.
• Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer. 2021 Jan.151:30-38. Pubmedid: 33285469.
• Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
• Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers (Basel). 2021 Aug.13(15). Pubmedid: 34359807. Pmcid: PMC8345430.
• Puri S, Saltos A, Perez B, Le X, Gray JE. Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep. 2020 Mar.22(4):31. Pubmedid: 32140986.
• Grass GD, Naghavi AO, Abuodeh YA, Perez BA, Dilling TJ. Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer. 2019 Jan.20(1):e1-e7. Pubmedid: 30268836.
• Oliver DE, Mohammadi H, Figura N, Frakes JM, Yamoah K, Perez BA, Wuthrick EJ, Naghavi AO, Caudell JJ, Harrison LB, Torres-Roca JF, Ahmed KA. Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Semin Radiat Oncol. 2019 Apr.29(2):111-125. Pubmedid: 30827449.
• Nichols D, Boyle TA, Noyes D, Latifi K, Feygelman V, Jackson I, Vujaskovic Z, Antonia S, Perez BA. Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. J Thorac Dis. 2018 Nov.10(11):6254-6260. Pubmedid: 30622798. Pmcid: PMC6297393.
• Oliver DE, Donnelly OG, Grass GD, Naghavi AO, Yang GQ, Dilling TJ, Perez BA. Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation. J Thorac Dis. 2018 Jul.10(7):4321-4327. Pubmedid: 30174879. Pmcid: PMC6106034.
• Abuodeh Y, Naghavi AO, Echevarria M, DeMarco M, Tonner B, Feygelman V, Stevens CW, Perez BA, Dilling TJ. Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in Postoperative Lung Cancer Radiotherapy Meta-analysis. Clin Lung Cancer. 2018 Jan.19(1):e123-e130. Pubmedid: 29107487.
• Oellers P, Mowery YM, Perez BA, Stinnett S, Mettu P, Vajzovic L, Light K, Steffey BA, Cai J, Dutton JJ, Buckley EG, Halperin EC, Marks LB, Kirsch DG, Mruthyunjaya P. Efficacy and Safety of Low-Dose Iodine Plaque Brachytherapy for Juxtapapillary Choroidal Melanoma. Am J Ophthalmol. 2018 Feb.186:32-40. Pubmedid: 29199010.
• Ahmed KA, Scott JG, Arrington JA, Naghavi AO, Grass GD, Perez BA, Caudell JJ, Berglund AE, Welsh EA, Eschrich SA, Dilling TJ, Torres-Roca JF. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. J Thorac Oncol. 2018 Aug.13(8):1121-1127. Pubmedid: 29733909. Pmcid: PMC7810135.
• Yuan Z, Fromm A, Ahmed KA, Grass GD, Yang GQ, Oliver DE, Dilling TJ, Antonia SJ, Perez BA. Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung. J Thorac Oncol. 2017 Sep.12(9):e135-e136. Pubmedid: 28502722.
• Zhang GG, Latifi K, Feygelman V, Chou KT, Huang TC, Dilling TJ, Perez BA, Moros EG. Ventilation Series Similarity: A Study for Ventilation Calculation Using Deformable Image Registration and 4DCT to Avoid Motion Artifacts. Contrast Media Mol Imaging. 2017 Sep.2017:9730380. Pubmedid: 29097945. Pmcid: PMC5623778.
• Ahmed KA, Grass GD, Creelan B, Gray J, Kim S, Dilling TJ, Antonia SJ, Perez BA. Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 May.98(1):224. Pubmedid: 28586976.
• Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun.133(2):331-338. Pubmedid: 28466250.
• Kelsey CR, Christensen JD, Chino JP, Adamson J, Ready NE, Perez BA. Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study. Pract Radiat Oncol. 2017 Jan.6(2):96-104. Pubmedid: 26723555.
• Ahmed KA, Creelan BC, Kim S, Dilling TJ, Perez BA. Safety and Tolerability of Extracranial Radiation Therapy and Immune Checkpoint Inhibitors Among Patients With Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):S201. Pubmedid: 27675781.
• Abuodeh YA, Naghavi AO, DeMarco M, Tonner B, Feygelman V, Stevens CW, Perez BA, Dilling TJ. Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in the PORT Meta-Analysis (MA): A Dosimetric Study. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E442. Pubmedid: 27674703.
• Grass GD, Naghavi AO, Frakes JM, Perez BA, Dilling TJ. Treatment of Stage III Non-Small Cell Lung Cancer Patients With Concurrent Chemotherapy and Radiation (70 Gy): Equivalent or Superior to 60 or 74 Gy of RTOG 0617?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E428-E429. Pubmedid: 27674664.
• Moding EJ, Castle KD, Perez BA, Oh P, Min HD, Norris H, Ma Y, Cardona DM, Lee CL, Kirsch DG. Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. Sci Transl Med. 2015 Mar.7(278):278ra34. Pubmedid: 25761890. Pmcid: PMC4360135.
• Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ. Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park). 2015 Dec.29(12):990-1002. Pubmedid: 26680224.
• Kirkpatrick JP, Kelsey CR, Palta M, Cabrera AR, Salama JK, Patel P, Perez BA, Lee J, Yin FF. Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer. 2014 Apr.120(7):942-954. Pubmedid: 24382744.
• Perez BA, von Isenburg MA, Yu M, Tuttle BD, Adams MB. Exploring the impact of tablet computers on medical training at an academic medical center. J Med Libr Assoc. 2013 Apr.101(2):154-157. Pubmedid: 23646032. Pmcid: PMC3634380.
• Perez BA, Ghafoori AP, Lee CL, Johnston SM, Li Y, Moroshek JG, Ma Y, Mukherjee S, Kim Y, Badea CT, Kirsch DG. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol. 2013.3:72. Pubmedid: 23565506. Pmcid: PMC3613757.
• Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, Jacks T. Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys. 2010 Mar.76(4):973-977. Pubmedid: 20206017. Pmcid: PMC2847457.
• Johnston SM, Perez BA, Kirsch DG, Badea CT. Phase-selective image reconstruction of the lungs in small animals using Micro-CT. Proc SPIE Int Soc Opt Eng. 2010 Feb.7622:76223G.1-76223G.9. Pubmedid: 21243034. Pmcid: PMC3018736.

Title: Heterogeneity of metastatic small cell lung cancer; implications for the design of effective immunotherapies
Sponsor: Florida Biomedical Research Program (FBRP)
PI: Perez, B.
Title: Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung cancer
Sponsor: Nat Institutes of Health
PI: Perez, B.